
Exercise and Psoriasis: A Conversation with Dr. Helen Young
Patients with psoriasis are at increased risk for cardiovascular disease —and lack of physical activity may be a driving cause.
Patients with psoriasis are at increased risk for cardiovascular disease —and lack of physical activity may be a driving cause.
The United States Food and Drug Administration (FDA) has approved deucravacitinib to treat psoriasis. Recently, 52-week efficacy and safety data of deucravacitinib were compared and contrasted with placebo and apremilast. The outcome of this comparative study lends support for the position of deucravacitinib in the spectrum of treatments for psoriasis.
Researchers at Cardiff University have created and launched The Official DLQI App, designed to measure the quality of life for people with skin conditions. The app is free to download in the Apple and Android stores and is now available in seven languages!
Annually, the IPC Board selects a specific subject of importance and commissions a group of experts to conduct a best evidence review. In 2021, IPC supported the BIOMAP collaboration to complete a systematic review on biomarkers. Last month, two new lay summaries were published by BIOMAP on this project.
Sotyktu™(deucravacitinib), an oral treatment for adults with moderate to severe plaque psoriasis. Sotyktu™ is the only approved TYK2 inhibitor worldwide and the first improvement in oral treatment for moderate to severe plaque psoriasis in nearly ten years.
Real-world evidence studies become crucial to achieving the evidence needed in clinical practice. But how are data evaluated in the complexity of the real world? Alexander Egeberg, MD, PhD, DMSc, discusses a present study that examined drug survival among 16,122 treatment courses of biologic therapy with either guselkumab, ixekizumab, secukinumab, ustekinumab, or adalimumab, using United Kingdom registry data.
Arcutis Biotherapeutics, Inc announced Arcutis Cares, a patient assistance program (PAP) for financially qualified uninsured and underinsured patients.
The 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN) was held Wednesday, July 6 – Friday, July 8, 2022, in Paris, France. The following congress report includes twelve summaries of presentations focusing on psoriasis. You can download the full report or read on for a brief look at some of the highlights.
Claro, a digital platform built to improve mental health for those with psoriasis who are living in Spain, the United Kingdom, and Italy.
The Society of Investigative Dermatology (SID) Annual Meeting returned to an in-person format in 2022 for the first time in two years. The following congress report includes a summary of the Eugene Farber lecture, three IPC lectures, and seven IPC poster presentations, all with a focus on psoriasis. You can download the full report or read on for a brief look at some of the highlights.
Eli Lilly announced a new formula for Taltz® that contains the same active ingredient as the original formulation, but patients experience significantly less pain at the injection site.
ZORYVE is the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved to treat plaque psoriasis. The product is expected to be available mid-August.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
The Next Era of Opportunity in Psoriasis: Spatial Transcriptomics